Concepedia

Michael Capparelli

MC

15

Publications

1K

Citations

13

H-Index

1987

Active since

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

Tris Pharma (United States)

Michael Capparelli is an author at Novartis (United States) specializing in medicine, natural sciences, and pharmacology.

Top concepts

Publications per year

1987–2020

15

Publications

15

Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits

Lawrence MacPherson, Erol K. Bayburt, Michael Capparelli et al. · Journal of Medicinal Chemistry · 1997 · 325 citations · Full text

Small-molecule WNK inhibition regulates cardiovascular and renal function

Ken Yamada, Hyi-Man Park, Dean F. Rigel et al. · Nature Chemical Biology · 2016 · 162 citations · Full text

, , +8

Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of Cathepsin B through Structure-Based Drug Design

Paul D. Greenspan, Kirk Clark, Rubén Tommasi et al. · Journal of Medicinal Chemistry · 2001 · 136 citations · Full text

A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase

Lauren G. Monovich, Richard B. Vega, Erik L. Meredith et al. · FEBS Letters · 2009 · 58 citations

Discovery of 4-((2 <i>S</i> ,4 <i>S</i> )-4-Ethoxy-1-((5-methoxy-7-methyl-1 <i>H</i> -indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases

Nello Mainolfi, Takeru Ehara, Rajeshri G. Karki et al. · Journal of Medicinal Chemistry · 2020 · 57 citations

Rows per page

1–5 of 15